source
- Merck projects continued investment and growth as Keytruda patent expiresMerck reported third‑quarter results on an investor call, saying sales expectations were above forecasts thanks to strong performance of subcutaneous Keytruda and the pulmonary arterial hypertensio…
- Eli Lilly lifts guidance by $10 billion as GLP‑1 sales outpace expectationsEli Lilly said its latest financial guidance is $10 billion higher than previously forecast, driven by strong sales of its GLP‑1 medicines. The company’s commercial performance has repeatedly excee…